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Abstract
Background
Randomized controlled trials (RCTs) pose specific challenges in rare and heterogeneous
neurological diseases due to the small numbers of patients and heterogeneity in disease
course. Two analytical approaches have been proposed to optimally handle these issues in
RCTs: covariate adjustment and ordinal analysis. We investigated the potential gain in effi-
ciency of these approaches in rare and heterogeneous neurological diseases, using Guil-
lain-Barre´ syndrome (GBS) as an example.
Methods
We analyzed two published GBS trials with primary outcome ‘at least one grade improve-
ment’ on the GBS disability scale. We estimated the treatment effect using logistic regres-
sion models with and without adjustment for prognostic factors. The difference between the
unadjusted and adjusted estimates was disentangled in imbalance (random differences in
baseline covariates between treatment arms) and stratification (change of the estimate due
to covariate adjustment). Second, we applied proportional odds regression, which exploits
the ordinal nature of the GBS disability score. The standard error of the estimated treatment
effect indicated the statistical efficiency.
Results
Both trials were slightly imbalanced with respect to baseline characteristics, which was cor-
rected in the adjusted analysis. Covariate adjustment increased the estimated treatment
effect in the two trials by 8% and 18% respectively. Proportional odds analysis resulted in
lower standard errors indicating more statistical power.
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Conclusion
Covariate adjustment and proportional odds analysis most efficiently use the available data
and ensure balance between the treatment arms to obtain reliable and valid treatment effect
estimates. These approaches merit application in future trials in rare and heterogeneous
neurological diseases like GBS.
Introduction
RCTs are the standard to investigate the effectiveness of medical interventions. However,
RCTs are challenging in rare heterogeneous diseases. The randomization process in RCTs
ensures that observed and unobserved patient characteristics on average are similar between
treatment arms[1]. However, it does not ensure full balance[1]. Different baseline risks for out-
come can arise between treatment arms, simply due to chance[1]. In diseases with large
between-patient differences in natural disease course, severity and outcome, small imbalances
in covariates between the treatment arms may, positively or negatively, affect the estimated
treatment effect.
Sample sizes in RCTs in rare diseases are usually small. Small trials are a subject to a greater
chance of imbalance than large trials[1]. Moreover, small RCTs can easily fail to detect treat-
ment benefits, due to lack of statistical power. In rare neurological disorders, such as inflam-
matory neuropathies like Guillain-Barre´ syndrome (GBS), Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN), this het-
erogeneity and rarity is a major challenge for conducting RCTs.
Two approaches to optimize RCT design and analysis that have been successfully applied in
other acute neurological diseases such as stroke and traumatic brain injury are covariate
adjustment and ordinal analysis[2–4]. (Table 1) Covariate adjustment is a statistical method
that adjusts the treatment effect for baseline risk on poor outcome in the treatment arms.
When the treatment arms are imbalanced, an unadjusted analysis is suboptimal to estimate the
treatment effect. In addition, previous studies found that covariate adjustment could increase
statistical power[1, 5–9]. Ordinal analysis is an approach to analyze a full ordinal outcome
scale instead of a dichotomized version. Although these techniques already have been success-
fully applied in stroke and traumatic brain injury, it is still relevant to study this in other dis-
eases like GBS, since the effect of the different approaches can work out differently in different
study settings. The most commonly used outcome in GBS is the ordinal GBS disability score,
consisting of seven categories. Usually the scale is dichotomized into favorable or unfavorable
outcome, or the improvement on the GBS disability score from admission calculated and
dichotomized as minimal one grade improvement. In ordinal analysis the outcome is not
dichotomized but analyzed as the full ordinal scale with proportional odds analysis, preventing
loss of information[10]. Simulation studies and empirical validation studies in other fields
have demonstrated that proportional odds analysis increases statistical power in RCTs[10–13].
To test the applicability and value of these approaches in rare and heterogeneous neurologi-
cal diseases, we use Guillain-Barre´ syndrome (GBS) as an example. GBS is a life-threatening
acute immune-mediated polyradiculoneuropathy[14, 15], which requires early diagnosis and
hospital admission for accurate monitoring, treatment and supportive care. Some patients
may show spontaneous and full recovery, while others require ventilation at an ICU for
months and remain severely disabled. Several RCTs have successfully been conducted in GBS
[16–18].
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We aimed to explore the potential benefit of covariate adjustment and proportional odds
analysis in rare and heterogeneous neurological diseases, compared to the conventional statis-
tical approaches. We hereto re-analyzed two RCTs in GBS.
Methods
Patient population
We analyzed data from two RCTs in GBS, the Plasma Exchange (PE) vs Intravenous Immuno-
globulin (IVIg) (PE vs IVIg) trial[17] and the IVIg and placebo versus IVIg and Methyl-Pred-
nisolone (MP) (IVIg vs MP) trial[18], conducted between 1986 and 2000. In the PE vs IVIg
trial, the control group received IVIg and the treatment group received PE. In the IVIg vs MP
trial, the patients receiving IVIg and placebo were considered as control patients and the
patients receiving IVIg and MP were considered as treated patients. The primary outcome in
both trials was improvement (corresponding to lower GBS disability scores) by one or more
grades on the GBS disability score after 4 weeks. The GBS disability score is an ordinal scale
ranging from 0 = healthy to 6 = dead. However, in order to estimate treatment effects for a pos-
itive outcome for all the analyses, we used the reversed GBS disability score at 4 weeks, to keep
the estimates easy to compare. For all the regression models used in this paper, higher numbers
(in outcome) mean better health outcomes.
Statistical analysis
The predicted probabilities for one grade improvement on the GBS disability score were calcu-
lated and used as a measure for baseline risk to indicate potential unbalance between the treat-
ment arms in baseline characteristics.
Table 1. Distribution of baseline predictors and outcome distribution in two randomized controlled trials in GBS.
PE vs IVIg trial IVIg + placebo vs IVIg
+ Methylprednisolon (IVIg vs MP) trial
Total
(n = 146)
Control
(PE)
(n = 73)
Treatment
(IVIg)
(n = 73)
Total
(n = 221)
Control (IVIg)
(n = 111)
Treatment
(IVIg+MP)
(n = 110)
Age (Median, Interquartile Range 25th-75th Percentile) 49 (32–63) 51 (33–66) 47 (32–61) 55 (35–67) 52 (35–67) 57 (34–68)
Preceding diarrhea 27 (19%) 16 (22%) 11 (15%) 60 (27%) 30 (27%) 30 (27%)
GBS disability score at admission
Able to walk over 10m open space with help 29 (20%) 16 (22%) 13 (18%) 58 (26%) 32 (30%) 26 (24%)
Bedridden or chair bound 92 (63%) 44 (60%) 48 (66%) 53 (49%) 78 (70%) 75 (68%)
Needs ventilation for at least a part of the day 25 (17%) 13 (18%) 12 (16%) 10 (5%) 1 (1%) 9 (8%)
Predicted probability of one or more grades
improvement on the GBS disability score after 4 weeks
0.43 0.41 0.45 0.62 0.64 0.60
One or more grades improvement on the GBS disability score after 4 weeks 63 (43%) 25 (34%) 38 (52%) 137 (62%) 63 (57%) 74 (67%)
GBS disability score after 4 weeks
0 = Healthy 0 (0%) 0 (0%) 0 (0%) 5 (2%) 0 (0%) 5 (5%)
1 = Minor symptoms 16 (11%) 6 (8%) 10 (14%) 37 (17%) 24 (22%) 13 (12%)
2 = Able to walk 10m unassisted but not able to run 30 (21%) 12 (16%) 18 (25%) 74 (34%) 31 (28%) 43 (39%)
3 = Able to walk over 10m open space with help 19 (13%) 9 (12%) 10 (14%) 22 (10%) 10 (9%) 12 (11%)
4 = Bedridden or chair bound 48 (33%) 27 (37%) 21 (29%) 54 (24%) 31 (28%) 23 (21%)
5 = Needs ventilation for at least a part of the day 31 (21%) 17 (23%) 14 (19%) 26 (12%) 14 (13%) 12 (11%)
6 = Dead 2 (1%) 2 (3%) 0 (0%) 3 (1%) 1 (1%) 2 (2%)
https://doi.org/10.1371/journal.pone.0211404.t001
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To estimate treatment effects, we used two commonly used primary (dichotomous) out-
comes in GBS trials as reference; (1) favorable outcome (0–2) on the GBS disability scale at 4
weeks as outcome and (2) minimal one grade improvement on the GBS disability score
between the moment of randomization and 4 weeks as outcome, both analyzed with binary
logistic regression without covariate adjustment. Consequently, these references were com-
pared with the two approaches under study: covariate adjustment and ordinal analysis.
Covariate adjustment
With covariate adjustment, conditional treatment effects are estimated with regression models.
Adjusting for GBS disability score at admission results in an estimated treatment effect for a
patient with a given GBS disability score, while unadjusted analysis results in an average esti-
mated treatment effect over all patients, irrespective of the GBS disability score. Unadjusted
analysis is expressed by the following formula:
log odds ðimprovementÞ ¼ aþ b � treatment
, where improvement is by one or more grades on the GBS disability score, and treatment is an
indicator for the randomization arm. The coefficients α and β indicate the intercept and
regression coefficient for treatment. In logistic regression, exp(β) indicates the odds ratio
(OR).
For adjusted analysis, we used three well-known predictors of outcome[19, 20]: age, preced-
ing diarrhea and GBS disability score at admission. The covariate adjusted model is expressed
by the following formula:
log odds ðimprovementÞ
¼ aþ b � treatment þ b1 � ageþ b2 � preceding diarrheaþ b3 � GBS disability score at admission
This results in an adjusted regression coefficient β for the estimated treatment effect. In the
trial analysis, the observed difference of the unadjusted and adjusted regression coefficient for
the treatment variable is a result of imbalance and stratification[8]. We hereto calculated the
linear predictor based on age, diarrhea and GBS disability score at admission. We then calcu-
lated the difference in treatment effect that was attributable to imbalance as the difference
between the mean value of the linear predictor between the treatment arms[8]. The remaining
part of the difference between the unadjusted and the adjusted treatment effect was attributed
to stratified estimation, i.e. conditioning on covariates[8].
Proportional odds analysis
For ordinal analysis we used proportional odds logistic regression to exploit the ordinal nature
of the GBS disability score. A proportional odds logistic regression model was fitted with the
GBS disability score collapsed to a 5-point scale. We combined both healthy (0) and minor
symptoms (1), as well as needs ventilation at least a part of the day (5) and dead (6) because of
small numbers in these extreme categories. We used the reversed GBS disability scale to esti-
mate treatment effects on a positive outcome, and to keep these estimates comparable to the
estimates of the other logistic regression models on positive dichotomous outcomes (improve-
ment and favorable outcome). The proportional odds model uses an ordinal outcome variable
with more than two possible categories. It estimates a common OR over all possible cut-offs of
the outcome scale. Next, we used the difference between the GBS disability score at admission
and the GBS disability score at four weeks as outcome. A proportional odds logistic regression
model was used to analyse the difference in GBS disability score.
Efficient design and analysis of randomized controlled trials in rare neurological diseases
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Treatment effect estimates
The coefficient β of the treatment effect and the corresponding standard error (SE) were calcu-
lated for the four approaches to analyse outcome, with and without covariate adjustment. The
SE of the treatment effect indicates the precision of the calculated treatment effect. The SEs in
the proportional odds regression models are expected to be smaller than those in the logistic
models. Both trials were analysed with complete case analysis, ignoring 1 and 4 patients with
incomplete baseline data. Statistical analyses were performed in R Statistical Software version
2.15.3 using the rms package (R Foundation for Statistical Computation, Vienna, Austria).
Results
Patient population and reference strategies
We analysed data from 146 patients in the PE vs IVIg trial and 221 patients in the IVIg vs IVIg
+MP trial. Both trials were slightly imbalanced with regard to the baseline characteristics. In
the IVIg vs IVIg+MP trial the treatment group (with MP) had a probability of 0.60 to improve
at least one grade on the GBS disability score compared to a predicted probability of 0.64 in
the control group (without MP). So without any treatment, the prognosis of the treatment arm
was slightly better. An opposite distribution of baseline covariates between treatment arms is
shown in the PE vs IVIg trial. The treatment group (PE) has a higher predicted probability
(0.45) to improve at least one grade on the GBS disability score compared to the control group
(IVIg; predicted probability 0.41, Table 1).
Regarding the actual outcome, 63 (57%) control patients treated with IVIg and placebo and
74 (67%) patients treated with IVIg and methylprednisolone improved minimal one grade on
the GBS disability score after 4 weeks. In the other trial, 25 (34%) control patients treated with
IVIg and 38 (52%) patients receiving PE improved minimal one grade on the GBS disability
score after 4 weeks (S1 Appendix).
The treatment under study in both trials had a positive effect on health outcomes. With the
reference strategy of logistic regression on a favorable GBS disability scale (0–2) at 4 weeks as
outcome, the estimated treatment OR was 1.80 (95% confidence interval (CI) 0.84–3.85, SE
0.39, p = 0.13) in the PE vs IVIg trial and 1.69 (95% CI 0.93–3.08, SE 0.31, p = 0.09) in the IVIg
vs IVIg+MP trial. The treatment effect estimates on one grade improvement were slightly
larger (Table 2).
Covariate adjustment
With covariate adjustment, the estimated treatment effect was larger in the IVIg vs IVIg+MP
trial, partly as a result of adjustment, which makes the estimates more extreme, and partly
because of the imbalance at baseline. Poorer prognosis at baseline for the intervention (IVIg
+ MP) group implied a +31% increase in the adjusted treatment effect (Table 3). The stratifica-
tion effect of adjustment was an additional 18% increase in the treatment effect (OR = 1.96). In
contrast, the treatment effect was smaller with adjustment for baseline characteristics in the PE
vs IVIg trial. The stratification effect increased the treatment effect with 8%, but the better
prognosis in the intervention (IVIg) group at baseline reduced the estimated treatment effect
by -24%. The net effect was a difference in treatment effect of -16%. These results were similar
for all binary and ordinal outcome analyses (Table 2).
Proportional odds analysis
For illustration of the proportional odds analyses we calculated the treatment effect estimates
(ORs) for each cut-off of the reversed ordinal scale. The common OR can be interpreted as the
Efficient design and analysis of randomized controlled trials in rare neurological diseases
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pooled estimate of these binary ORs. The treatment under study in both trials had a positive
effect on health outcomes in all the ordinal analyses. In the PE vs IVIg trial the ORs over each
cut-off were relatively similar (Fig 1C and 1D. The common OR was similar as well, but the SE
and CI were smaller. In the IVIg vs IVIg+MP trial, the ORs were more variable (Fig 1A and
1B. The common OR was less extreme compared to ORs for the cut-off used in the reference
approach (0–2 vs. 3–6 and minimal one grade improvement vs. no improvement). But again,
the SE and CI were smaller. This can also be seen in Table 2; in all analyses, the proportional
odds analysis on the GBS disability score after four weeks and on the improvement on the GBS
disability score resulted in lower SEs of the treatment effect compared to the binary
approaches.
Discussion
In this study we assessed the potential benefit of the use of covariate adjustment and propor-
tional odds analysis in RCTs compared to the conventional method, by reanalyzing two GBS
trials. We found that covariate adjustment increased the estimated treatment effect in one
trial, and decreased the estimated treatment effect in the other trial, due to imbalances in
Table 2. Treatment effect analysis: Unadjusted and adjusted binary and proportional odds logistic regression.
PE vs IVIg
trial
(n = 146)
Unadjusted
Adjusted�
IVIg + placebo vs
IVIg
+ Methylprednisolon
(IVIg vs MP) trial
(n = 221)
Unadjusted
Adjusted�
Binary logistic regression–
GBS disability 3–6 vs 0–2 §
OR
(95%
CI)
1.90 (0.93–
3.87)
1.80 (0.84–
3.85)
1.27
(0.75–
2.15)
1.69
(0.93–
3.08)
SE 0.36 0.39 0.27 0.31
P-value 0.08 0.13 0.38 0.09
Binary logistic regression–improvement on GBS
disability score
OR
(95%
CI)
2.08 (1.07–
4.06)
1.95 (0.96–
4.00)
1.57
(0.91–
2.71)
1.96
(1.08–
3.56)
SE 0.34 0.36 0.28 0.31
P-value 0.03 0.06 0.11 0.03
Proportional odds logistic regression–reversed
GBS disability score at 4 weeks ^
OR
(95%
CI)
1.76 (0.98–
3.19)
1.76 (0.98–
3.19)
1.12
(0.70–
1.80)
1.41
(0.87–
2.28)
SE 0.30 0.30 0.24 0.25
P-value 0.06 0.06 0.63 0.17
Proportional odds logistic regression–Δ GBS
disability score (grades improvement between
admission and 4 weeks)
OR
(95%
CI)
1.93 (1.07–
3.49)
1.80 (0.99–
3.27)
1.43
(0.89–
2.30)
1.34
(0.89–
2.32)
SE 0.30 0.30 0.24 0.25
P-value 0.03 0.05 0.14 0.14
�Adjustment for age, preceding diarrhea and GBS disability score at admission.
§ 0 = Healthy / 1 = Minor symptoms / 2 = Able to walk 10m unassisted but not able to run / 3 = Able to walk over
10m open space with help / 4 = Bedridden or chair bound / 5 = Needs ventilation for at least a part of the day /
6 = Dead
^ In order to estimate the treatment effect for a positive outcome, we used the reversed GBS disability score at 4
weeks
https://doi.org/10.1371/journal.pone.0211404.t002
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baseline characteristics between the treatment arms. Although such imbalances are fully due to
chance if a proper randomization procedure is followed, our results illustrate that their impact
on interpretability of treatment effect estimates can be substantial and can be different in sev-
eral study settings. We found that the proportional odds analysis resulted in lower standard
errors and thus smaller confidence intervals of the treatment effect estimate compared to the
conventional method of logistic regression on dichotomized outcome measures. Thus, dichot-
omization of ordinal outcome measures does not merit application. In future trials in rare and
heterogeneous neurological diseases like GBS both covariate adjustment and proportional
odds analysis are advised.
Table 3. Results of unadjusted and adjusted binary logistic regression analysis of the effect of treatment versus control on GBS disability score at four weeks in both
PE vs IVIg trial (n = 146) and the IVIg + placebo vs IVIg + Methylprednisolon (IVIg vs MP) trial (n = 221).
OR Coefficient Absolute difference in
treatment effect between
adjusted and unadjusted
Imbalance
between
treatment arms
Relative difference in
treatment effect between
adjusted and unadjusted due
to imbalance
Relative difference in
treatment effect between
adjusted and unadjusted due
to stratification
PE vs IVIg trial
Unadjusted 2.08 0.73
Adjusted for age, preceding
diarrhea and GBS disability score
at admission
1.95 0.67 - 0.06^ -0.12 -16%� 8%#
IVIg vs MP trial
Unadjusted 1.57 0.45
Adjusted for age, preceding
diarrhea and GBS disability score
at admission
1.96 0.67 0.22^ 0.14 31%� 18%#
^ Adjusted coefficient–Unadjusted coefficient
� Imbalance between treatment arms / Unadjusted coefficient
# (Absolute difference in treatment effect between adjusted and unadjusted—Imbalance between treatment arms) / Unadjusted coefficient.
https://doi.org/10.1371/journal.pone.0211404.t003
Fig 1. Treatment effect analysis: forest plots of the adjusted binary and proportional odds logistic regression in the IVIg + placebo vs IVIg
+ Methylprednisolon (IVIg vs MP) trial (a and b) and PE vs IVIg trial (c and d) show smaller confidence intervals for the common odds ratio
compared to the binary estimates.
https://doi.org/10.1371/journal.pone.0211404.g001
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Covariate adjustment
On expectation, covariate adjustment leads to more extreme treatment effect estimates and
larger standard errors for non-linear regression models.[21] The p values are a function of the
treatment effect estimates and standard error. With covariate adjustment the increase in treat-
ment effect estimate will outweigh increased in standard error and the p values will be lower
compared to unadjusted analysis[21].
Indeed, we found increased standard errors in all adjusted analyses compared to the unad-
justed analyses. The better prognosis in the treatment group decreased the treatment effect
estimate β after covariate adjustment in the PE vs IVIg trial. In the IVIg vs MP trial, the treat-
ment group had a lower probability of favorable outcome. Therefore, in the IVIg vs MP trial
covariate adjustment led to a larger β and a smaller p value.
Covariate adjustment increases statistical power, despite the larger standard error.[1, 7]
When there are no baseline imbalances, the adjusted conditional estimates will be more
extreme than the unadjusted marginal estimates[22]. However, the size and the direction of
the difference between the unadjusted and adjusted estimates are dependent on the strength of
the prognostic factors and the imbalance in baseline risk between the treatment- and control
group in the specific trial and this is shown in our study. When investigating the effectiveness
of a medical intervention in rare and heterogeneous neurological diseases, such as GBS, one
has to deal with small sample sizes. We therefore recommend performing covariate adjustment
in future trials in rare and heterogeneous neurological diseases. For GBS this covariate adjust-
ment should be applied with known predictors for (functional) outcome, specifically age, pre-
ceding diarrhea, GBS disability score and MRC sum score[19, 20].
The outcome ‘minimal one grade improvement’ implicitly involves a form of covariate
adjustment. The baseline disease severity of the patient is taken into account in the analysis by
estimating improvement for each patient from his or her own starting position at admission
(Table 4). This principle of a measure of change between baseline and follow up seems attrac-
tive to control for baseline imbalance. However, analyzing change does not control for baseline
imbalance because of regression to the mean[23, 24]; baseline values are negatively correlated
with change because patients with high scores at baseline generally improve more than those
with low scores[25]. Therefore covariate adjustment with the absolute baseline value is still
preferable over implicitly taking into account baseline severity in the outcome measure
‘improvement’. Moreover, disease severity at baseline is not the only covariate we could adjust
for. Especially, the age of the patient will be an important covariate in most neurological
diseases.
Thus, in general, ignoring baseline imbalance between treatment arms in trials may cause
invalid conclusions on both the magnitude and significance of the treatment effect estimate
compared to analysis using covariate adjustment. The impact on interpretability of treatment
effect estimates can be substantial and can be different in several study settings. When design-
ing a trial, the analysis plan should be precisely pre-specified. Also, the covariates that will be
used for adjustment should be pre-specified. Previous studies have shown that the stronger the
relation of the covariates with outcome, the larger the increase in statistical power with covari-
ate adjustment will be[5, 26, 27]. In GBS, predictors of outcome are relatively well known[19,
20] and therefore pre-specifying important baseline variables for covariate adjustment is possi-
ble in GBS trials.
Proportional odds analysis
It is evident that the GBS disability scale is not a linear scale. For example, improvement from
“needs ventilation for at least a part of the day” to “bedridden or chair bound” is not the same
Efficient design and analysis of randomized controlled trials in rare neurological diseases
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improvement as the improvement from “able to walk over 10m open space with help” to “able
to walk 10m unassisted but not able to run”. However, whether or not the ordinal outcome
under study is a linear scale is not relevant for the validity of the proportional odds analysis.
Proportional odds analysis merely requires ordering of outcomes. The proportional odds anal-
ysis estimates the treatment effect on each cut-off of the scale, instead of estimating the treat-
ment effect on the difference between the averages scores in the treatment arms, as linear
regression. The proportional odds model results in a common OR, which is interpretable as a
pooled OR over all ORs for the different cut-offs. The common OR is formally valid if the ORs
for each cut-off are the same (the proportional odds assumption). We can, however, interpret
the common OR as a summary measure of the treatment effect, even if the ORs differs slightly
per cut-off[12, 28]. The common OR can also be interpreted as the average shift over the total
ordinal outcome scale caused by the treatment under study[10–13]. Moreover, simulation
studies have shown that ordinal analysis is more efficient than binary analysis, even if the pro-
portional odds assumption is violated[11]. Because the ordinal analysis uses the full ordinal
outcome scale instead of one dichotomy, the variability will be smaller compared to binary
analysis. This was confirmed in our study, where the proportional odds resulted in lower stan-
dard errors compared to the binary approaches. Although the importance of applying propor-
tional odds analysis already has been assessed in other diseases, it is still relevant to study this
for specific cases like GBS. For example it is important to have more insight in the effect of
treatment on the different cut-offs for the specific ordinal outcome measure, in this case the
GBS disability score, and see if the proportional odds assumption holds.
In the PE vs IVIg trial, the ORs for each cut-off were very similar and as a result the com-
mon OR was also similar. Thus, with the smaller SE, the p value was lower. In contrast, in the
IVIg vs IVIg+MP trial, the ORs were more scattered. One explanation is chance: the ORs for
the different cut-offs are uncertain, especially at the tails of the outcome scale where numbers
are usually small. However, almost all binary ORs have confidence intervals that overlap.
Another explanation is that the effect is truly different for different cut-offs, although this is
Table 4. Characteristics of four methods of treatment effect analysis in GBS trials. Approach in bold is the recom-
mended approach.
Takes into account
baseline imbalance
Takes into account
ordinal nature of the outcome measure
Unadjusted binary logistic regression
on cutoff for GBS disability score
NO NO
Adjusted binary logistic regression
on cutoff for GBS disability score
YES NO
Unadjusted binary logistic regression
on� 1 grade improvement on GBS disability score
PARTLY� NO
Adjusted binary logistic regression
on� 1 grade improvement on GBS disability score
YES NO
Unadjusted proportional odds logistic regression
on GBS disability score
NO YES
Adjusted proportional odds logistic regression
on GBS disability score
YES YES
Unadjusted proportional odds logistic regression
on Δ GBS disability score
PARTLY� YES
Adjusted proportional odds logistic regression
on Δ GBS disability score
YES YES
�Only baseline GBS disability score, no other covariates.
https://doi.org/10.1371/journal.pone.0211404.t004
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clinically unlikely. The cut-off chosen in the reference approach in the analysis of improve-
ment appeared to be the most optimal cut-off from a statistical perspective, since it was the
only cut-off resulting in a significant treatment effect.
However, if we assume a relatively constant treatment effect across the different cut-offs of
an ordinal outcome scale, it is unpredictable which cut-off will show the strongest effect.
Therefore, the ordinal analysis is a ‘safe’ choice and the common OR is a fair representation of
the effect of treatment on the ordinal outcome compared to the binary approach, because it
takes into account improvement over all levels of the GBS disability score. Since it is also more
efficient, we recommend the use of the full ordinal outcome scale in future trials in rare and
heterogeneous neurological diseases. In observational studies, ordinal analyses could be com-
bined with propensity score methods to maximize statistical power.
Limitations
Patients with missing covariate data were excluded from the analyses. Data from 367 patients
were analyzed rather than 372 patients in the original analyses. We did not assess heteroge-
neous treatment effects according to baseline risk, which could influence the ability of covari-
ate adjustment to improve the statistical power in an RCT. In this study we only investigated
GBS which may not fully be representative for other neurological disorders, although covariate
adjustment and proportional odds analysis have shown advantages in other fields, such as
stroke and traumatic brain injury[3, 4, 7, 12].
Conclusion and implications
Covariate adjustment corrects for baseline imbalance and increases power. Proportional odds
analysis optimally exploits the ordinal nature of outcome scales. A combined approach is
advised for reliable and efficient estimation of treatment effects in small RCTs in rare and het-
erogeneous diseases like GBS.
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